Glenmark, Cosmo get market authorization for Winlevi from EC

18 Nov 2025 Evaluate

Glenmark Pharmaceuticals (Glenmark) and Cosmo Pharmaceuticals N.V. (SIX: COPN) (Cosmo) have received Marketing Authorization (MA) for Winlevi (clascoterone 10 mg/g cream) from European Commission (EC), following the positive opinion issued by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) on August 25, 2025.

Winlevi is authorized in EU for the treatment of acne vulgaris in both adults and adolescents aged 12 to below 18 years, with usage in adolescents limited to facial application. With receipt of this approval, Glenmark will initiate commercializing Winlevi across 15 countries in EU namely Bulgaria, the Czech Republic, Denmark, Finland, France, Hungary, Iceland, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Spain and Sweden.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Glenmark Pharma Share Price

1961.50 -12.65 (-0.64%)
05-Dec-2025 14:48 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1801.35
Dr. Reddys Lab 1275.30
Cipla 1517.15
Zydus Lifesciences 930.00
Lupin 2090.45
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×